Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease.
We studied 15 patients with chronic coronary artery disease (13 men aged 62 +/- 8 years) undergoing dobutamine (5 to 40 microg/kg/min) echocardiography at the end of two 15-day treatment periods with placebo and trimetazidine (20 mg 3 times daily) given in random order, according to a double-blind, crossover design. Results show that trimetazidine improves resting left ventricular function and reduces the severity of dobutamine-induced ischemic myocardial dysfunction.
Istituto Scientifico H. San Raffaele, Milan, Italy.
C
C
Lu
P
P
Dabrowski
G
G
Fragasso
S L
SL
Chierchia
D000284:Administration, Oral; D003327:Coronary Disease / Q000150:complications / Q000000981:diagnostic imaging / Q000503:physiopathology*; D018592:Cross-Over Studies; D004280:Dobutamine; D004334:Drug Administration Schedule; D004452:Echocardiography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014292:Trimetazidine / Q000008:administration & dosage / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology
D014665:Vasodilator Agents; D004280:Dobutamine; D014292:Trimetazidine